Biomunex Pharmaceuticals Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Investors
  • 3

Biomunex Pharmaceuticals General Information

Description

Developer of immunotherapies through a bispecific antibody intended to developing therapeutics in the area of immuno-oncology. The company's platform offers to develop drug candidates with high anti-tumor potential, superior manufacturability and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks, in a timely and cost-effective manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 14 avenue d'Eylau
  • 75116 Paris
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biomunex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Seed Round Completed Generating Revenue
3. Accelerator/Incubator Completed Startup
2. Grant 01-Jan-2016 Completed Startup
1. Grant 01-Jan-2014 Completed Startup
To view Biomunex Pharmaceuticals’s complete valuation and funding history, request access »

Biomunex Pharmaceuticals Executive Team (4)

Name Title Board Seat Contact Info
Pierre-Emmanuel Gerard Co-Founder & Chief Executive Officer
Eugene Zhukovsky Ph.D Chief Scientific Officer
Jean-Pierre Mach Co-Founder
To view Biomunex Pharmaceuticals’s complete executive team members history, request access »

Biomunex Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Agoranov Accelerator/Incubator 000 0000 000000 0
To view Biomunex Pharmaceuticals’s complete investors history, request access »